¼¼°èÀÇ ¹Ì¸¸¼º°Å´ë B¼¼Æ÷ ¸²ÇÁÁ¾(DLBCL) Ä¡·áÁ¦ ½ÃÀå(2024-2028³â)
Global diffuse large B-Cell lymphoma (DLBCL) therapeutics market 2024-2028
»óǰÄÚµå : 1502435
¸®¼­Ä¡»ç : TechNavio
¹ßÇàÀÏ : 2024³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 177 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,500 £Ü 3,531,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,000 £Ü 5,650,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¹Ì¸¸¼º°Å´ë B¼¼Æ÷ ¸²ÇÁÁ¾(DLBCL) Ä¡·áÁ¦ ½ÃÀå(2024-2028³â)

Technavio´Â ¹Ì¸¸¼º°Å´ë B¼¼Æ÷ ¸²ÇÁÁ¾(DLBCL) Ä¡·áÁ¦ ½ÃÀåÀ» ¸ð´ÏÅ͸µÇϰí ÀÖÀ¸¸ç, 2023-2028³â 22¾ï 4,980¸¸ ´Þ·¯, ¿¹Ãø ±â°£ Áß CAGRÀº 8.09%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ¹Ì¸¸¼º°Å´ë B¼¼Æ÷ ¸²ÇÁÁ¾(DLBCL) Ä¡·áÁ¦ ½ÃÀåÀÇ ÀüüÀûÀÎ ºÐ¼®, ½ÃÀå ±Ô¸ð¡¤¿¹Ãø, µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ¾à 25°³ º¥´õ¸¦ ´Ù·é º¥´õ ºÐ¼® µîÀ» Á¦°øÇÕ´Ï´Ù.

ÇöÀçÀÇ ½ÃÀå ½Ã³ª¸®¿À, Ãֽе¿Çâ°ú ÃËÁø¿äÀÎ, ½ÃÀå ȯ°æ Àüü¿¡ °üÇÑ ÃֽŠºÐ¼®À» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ½ÃÀåÀº °í·ÉÀÚ Àα¸ÀÇ Áõ°¡, DLBCLÀÇ ÀÌȯÀ² Áõ°¡, Àç¹ß ¶Ç´Â ³­Ä¡¼º DLBCL ȯÀÚ¿¡ ´ëÇÑ Ä¡·áÁ¦ ½ÂÀÎÀÇ Áõ°¡¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
±âÁسâ 2024
Á¾·á³â 2028
¿¹Ãø ±â°£ 2024-2028
¼ºÀå ¸ð¸àÅÒ °¡¼Ó
Àü³â´ëºñ 2024³â 7.32%
CAGR 8.09%
ÁõºÐ¾× 22¾ï 4,980¸¸ ´Þ·¯

º» Á¶»ç¿¡¼­´Â ±â¼úÀÇ Áøº¸¸¦ ÇâÈÄ ¼ö³â°£ ¹Ì¸¸¼º°Å´ë B¼¼Æ÷ ¸²ÇÁÁ¾(DLBCL) Ä¡·áÁ¦ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿äÀÎÀÇ Çϳª·Î ½Äº°Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ È¯ÀÚ Áö¿ø ÇÁ·Î±×·¥ÀÇ Áõ°¡ ¹× Àü·«Àû Á¦ÈÞ´Â ½ÃÀåÀÇ Å« ¼ö¿ä·Î ¿¬°áµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå ±¸µµ

Á¦3Àå ½ÃÀå ±Ô¸ðÀÇ Æò°¡

Á¦4Àå ½ÃÀå ±Ô¸ð ½ÇÀû

Á¦5Àå Five forces ºÐ¼®

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­ : ¿ëµµº°

Á¦7Àå ½ÃÀå ¼¼ºÐÈ­ : Á¦Ç°º°

Á¦8Àå °í°´ »óȲ

Á¦9Àå Áö¿ªº° »óȲ

Á¦10Àå ÃËÁø¿äÀΡ¤°úÁ¦¡¤±âȸ¡¤¾ïÁ¦¿äÀÎ

Á¦11Àå °æÀï ±¸µµ

Á¦12Àå °æÀï ºÐ¼®

Á¦13Àå ºÎ·Ï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Diffuse Large B-Cell Lymphoma (Dlbcl) Therapeutics Market 2024-2028

Technavio has been monitoring the diffuse large b-cell lymphoma (DLBCL) therapeutics market and is forecast to grow by USD 2249.8 mn during 2023-2028, accelerating at a CAGR of 8.09% during the forecast period. Our report on the diffuse large b-cell lymphoma (DLBCL) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing geriatric population, increasing incidence of DLBCL, and increasing approval of therapeutics for patients with relapsed or refractory DLBCL.

Market Scope
Base Year2024
End Year2028
Series Year2024-2028
Growth MomentumAccelerate
YOY 20247.32%
CAGR8.09%
Incremental Value$2249.8mn

Technavio's diffuse large b-cell lymphoma (DLBCL) therapeutics market is segmented as below:

By Application

By Product

By Geography

This study identifies the technological advances as one of the prime reasons driving the diffuse large b-cell lymphoma (DLBCL) therapeutics market growth during the next few years. Also, increasing patient support programs and strategic alliances will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the diffuse large b-cell lymphoma (DLBCL) therapeutics market covers the following areas:

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading diffuse large b-cell lymphoma (DLBCL) therapeutics market vendors that include AbbVie Inc., ADC Therapeutics SA, Amgen Inc., Bayer AG, BeiGene Ltd., Bristol Myers Squibb Co., Celltrion Healthcare Co. Ltd., CTI BioPharma Corp., Erytech Pharma SA, F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., Seagen Inc., Spectrum Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.. Also, the diffuse large b-cell lymphoma (DLBCL) therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Historic Market Size

5 Five Forces Analysis

6 Market Segmentation by Application

7 Market Segmentation by Product

8 Customer Landscape

9 Geographic Landscape

10 Drivers, Challenges, and Opportunity/Restraints

11 Competitive Landscape

12 Competitive Analysis

13 Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â